Giving men the support they need
source : http://www.foxnews.com/health/2013/06/27/women-cancer-support-group-just-for-men/
source : http://www.foxnews.com/health/2013/06/27/women-cancer-support-group-just-for-men/
To reduce the need for these second surgeries, four Johns Hopkins graduate students have designed a device to allow pathologists to quickly inspect excised breast tissue within 20 minutes, while the patient is still in the operating room. …
Researchers from the Centre for Genomic Regulation led by Miguel Beato have, in an article published in the journal Cell Reports, just revealed that one of these molecules (PLK1 kinase), up to now thought to be related to cancer, can also be crucial for the proper functioning of the cell. PLK1 had always been associated with breast cancer due to its role in cell division. …
source : http://www.foxnews.com/health/2013/06/24/menopause-hormone-use-not-linked-with-cognitive-problems/
source : http://www.foxnews.com/health/2013/06/25/breast-fed-children-more-likely-to-climb-social-ladder/
The team led by Spanish National Cancer Research Centre researcher Óscar Fernández-Capetillo, head of the Genomic Instability Group, together with researchers from the National Cancer Institute in the US, have participated in a study that describes the causes that explain why tumours with BRCA1 and BRCA2 mutations stop responding to PARP inhibitor drugs. "PARP inhibitors are only toxic in tumours that have an impaired DNA repair mechanism, such as those that contain BRCA1/2 mutations" says María Nieto-Soler, a researcher from Fernández-Capetillo’s team…
Susan G. Komen for the Cure has a new CEO. The breast cancer charity announced the appointment of Judith A. Salerno on Monday. Salerno replaces Nancy Brinker, the charity's founder, who announced last summer she would step down following an onslaught of criticism over its decision to stop giving grants to Planned Parenthood for breast cancer screenings. That decision was quickly reversed. Salerno is executive director and chief operating officer of the Institute of Medicine of the National Academies, a prestigious group that advises the government about health and science. Brinker founded the Dallas-based charity in honor of her sister, who died of breast cancer in 1980. It grew into a fundraising powerhouse, and its signature color of pink has become synonymous with breast cancer awareness.source : http://www.foxnews.com/health/2013/06/17/komen-breast-cancer-charity-names-new-ceo/
A new study has pinpointed a single gene that appears to both strengthen the heart –  without exercise – and halt the spread of breast cancer. Researchers at Case Western Reserve University found that the gene HEXIM1, discovered in 2012, not only suppressed the spread of breast cancer in mouse models, but also made the mice’s hearts healthier. with respect to enhanced strength and size. Normally, exercise helps to strengthen the heart and increase its size. However, researchers found that when the HEXIM1 gene was re-expressed in adult mouse hearts, their hearts grew in weight and size - without exercise. Researchers say this discovery has the potential to help treat people with cardiovascular disease. “Our Cleveland-based collaborative research teams revealed that increasing HEXIM1 levels brought normal functioning hearts up to an athletic level, which could perhaps stand up to the physical insults of various cardiovascular diseases,” said Michiko Watanabe, professor of pediatrics, genetics, and anatomy at Case Western Reserve School of Medicine and director of Pediatric Cardiology Fellowship Research at Rainbow Babies and Children's Hospital. Common cardiovascular diseases like hypertension and heart failure create a shortage of both oxygen and necessary nutrients in the heart muscles, preventing blood from circulating at a satisfactory rate. This ultimately results in a distended heart, which can continually grow weaker and has the potential to stop at any given moment. However, researchers showed that the artificial enhancement of HEXIM1 led to increased blood vessel growth and enhanced overall functionality of the heart. In essence, HEXIM1 could potentially serve as a therapeutic target for the treatment of heart disease. Researchers also found that HEXIM1 increased the number and density of blood vessels in the heart, decreased the animals’ resting heart rates and allowed the transgenic heart to circulate more blood per heartbeat.  The study also demonstrated that untrained genetically altered mice with the HEXIM1 gene were capable of running twice as long compared to unaltered mice. Lead researcher Monica Montano, associate professor of pharmacology, Case Comprehensive Cancer Center member, and creator of the mice for the heart and breast cancer research, was very proud of the research’s findings. “Our promising discovery reveals the potential for HEXIM1 to kill two birds with one stone – potentially circumventing heart disease as well as cancer, the country's leading causes of death,” Montano stated. The study’s results add to previous findings from the team’s research, which revealed last year that increasing levels of HEXIM1 expression led to the inhibition of breast cancer metastasis. Given the discovery of the gene’s two therapeutic benefits, the researchers are currently developing a more potent version of the drug hexamethylene-bisacetamide, which is meant to enhance HEXIM1 expression. “Many cancer drugs have detrimental effects on the heart,” said Dr. Mukesh K. Jain, professor of medicine and director of Case Cardiovascular Research Institute at Case Western Reserve School of Medicine. “It would be beneficial to have a cancer therapeutic with no adverse effects on the heart and perhaps even enhance its function.” The research was published in the peer-reviewed journal Cardiovascular Research.source : http://www.foxnews.com/health/2013/06/14/newly-discovered-gene-strengthens-heart-fights-breast-tumors/
A ruling by the Supreme Court that human genes can't be patented is expected to increase access and drop the cost for tests for gene mutations that greatly raise the risk of developing breast or ovarian cancer. In a bit of a mixed message, the court unanimously decided that certain types of gene tests may still be protected by patents, yet it struck down patents that a company has long held for BRCA genes. The company makes the only test for two of those breast cancer genes, BRCA1 and BRCA2. “It appears that it will allow the market to open up so that other laboratories can offer the test,” said Rebecca Nagy, a genetics counselor at Ohio State University and president of the National Society of Genetic Counselors. And that should make the tests cheaper and available to more women, she said. Hours after the ruling, one company - DNATraits, part of Houston-based Gene By Gene, Ltd. - said it would offer BRCA gene testing in the United States for $995 - less than a third of the current price. A primer on the case: Q: What did the court say? …
The work represents a major step toward truly individualized breast cancer prevention in women at high risk for the disease based on their age, family history of breast cancer, and personal medical history. "Our study reveals the first known genetic factors that can help predict which high-risk women should be offered breast cancer prevention treatment and which women should be spared any unnecessary expense and risk from taking these medications," said the study’s lead scientist, James N. Ingle, M.D., professor of oncology at the Mayo Clinic in Rochester, Minn. "We also discovered new information about how the drugs tamoxifen and raloxifene work to prevent breast cancer." Ingle and Mayo-based colleagues in the NIH Pharmacogenomics Research Network (PGRN) conducted the study in collaboration with PGRN-affiliated researchers at the RIKEN Center for Genomic Medicine in Tokyo. …